Availability of experimental therapy outside oncology randomized clinical trials in the United States

Journal of Clinical Oncology

Volumn 28, Issue 34, 2010, Pages 5067-5073

  Hamilton, Erika P ^a   Lyman, Gary H ^a   Peppercorn, Jeffrey ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

ARTICLE; CANCER SURVIVAL; DRUG APPROVAL; EXPERIMENTAL THERAPY; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; NEOPLASM; ONCOLOGY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UNITED STATES;

HUMANS; NEOPLASMS; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPIES, INVESTIGATIONAL; UNITED STATES;

EID: 79951927366     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.6567     Document Type: Article

References (30)

1. Joffe S, Cook E, Clark J, et al: Altruism among participants in cancer clinical trials. Proc Am Soc Clin Oncol 22:523, 2003 (abstr 2103)
2. Agrawal M, Grady C, Fairclough DL, et al: Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol 24:4479-4484, 2006 (Pubitemid 46630987)
3. Joffe S, Weeks JC: Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst 94:1847-1853, 2002
4. Poole SG, Dooley MJ: Off-label prescribing in oncology. Support Care Cancer 12:302-305, 2004 (Pubitemid 38647853)
5. Peppercorn J, Burstein H, Miller FG, et al: Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol 26:5994-6000, 2008
6. Jacobson PD, Parmet WE: A new era of unapproved drugs: The case of Abigail Alliance v Von Eschenbach. JAMA 297:205-208, 2007 (Pubitemid 46089737)
7. Abernethy AP, Raman G, Balk EM, et al: Systematic review: Reliability of compendia methods for off-label oncology indications. Ann Intern Med 150:336-343, 2009
8. Rettig RA Jacobsen PD, Farquhar CM , et al: False Hope: Bone Marrow Transplantation for Breast Cancer. New York, NY, Oxford University Press, 2007
9. Glickman SW, McHutchison JG, Peterson ED, et al: Ethical and scientific implications of the globalization of clinical research. N Engl J Med 360:816-823, 2009
10. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
11. Peppercorn J, Blood E, Winer E, et al: Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109:1239-1246, 2007 (Pubitemid 46466549)
12. Kjaergard LL, Als-Nielsen B: Association between competing interests and authors' conclusions: Epidemiological study of randomised clinical trials published in the BMJ. BMJ 325:249, 2002
13. Gish RG, Porta C, Lazar L, et al: Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25:3069-3075, 2007
14. Deenik W, van der Holt B, Verhoef GE, et al: High- vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia: A prospective randomized phase III study. Ann Hematol 86:117-125, 2007 (Pubitemid 44964003)
15. Noda K, Ohashi Y, Sugimori H, et al: Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: Treatment with immunomodulator, more is not better. Gynecol Oncol 101:455-463, 2006 (Pubitemid 43729978)
16. Deshmane V, Krishnamurthy S, Melemed AS, et al: Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 25:4967-4973, 2007 (Pubitemid 350220429)
17. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25:4779-4786, 2007 (Pubitemid 350086481)
18. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
19. Mounier N, Spina M, Gabarre J, et al: AIDS-related non-Hodgkin lymphoma: Final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107:3832-3840, 2006 (Pubitemid 43726784)
20. Dörr W, Herrmann T: Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy : Results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter study. Strahlenther Onkol 183:121-127, 2007 (Pubitemid 46364899)
21. Flaig TW, Tangen CM, Hussain MH, et al: Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 26:1532-1536, 2008
22. Gridelli C, Gallo C, Ceribelli A, et al: Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: The GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8:500-512, 2007 (Pubitemid 46805905)
23. Lorigan P, Verweij J, Papai Z, et al: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25:3144-3150, 2007 (Pubitemid 47218064)
24. Clark WF, Garg AX, Blake PG, et al: Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA 290:1351-1355, 2003 (Pubitemid 37442632)
25. Antman KH, Rowlings PA, Vaughan WP, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870-1879, 1997
26. Harari PM: Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J Clin Oncol 15:2050-2055, 1997
27. Easterbrook PJ, Berlin JA, Gopalan R, et al: Publication bias in clinical research. Lancet 337:867-872, 1991
28. Stafford RS: Regulating off-label drug use: Rethinking the role of the FDA. N Engl J Med 358:1427-1429, 2008
29. Food and Drug Administration, HHS: Expanded access to investigational drugs for treatment use. Final rule. Fed Regist 74:40900-40945, 2009
30. American Society of Clinical Oncology: Reimbursement for cancer treatment: Coverage of offlabel drug indications. J Clin Oncol 24:3206-3208, 2006